Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII

Investor Call with CEO, George Magrath, M.D., M.B.A., M.S. on December 5, 2023

FARMINGTON HILLS, Mich., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the Company’s CEO, George Magrath M.D., M.B.A., M.S., will deliver a presentation at the Ophthalmology Innovation Summit (OIS XIII), to take place in San Diego, CA on December 1-2, 2023.

Dr. Magrath will also host a conference call for the investment community on Tuesday, December 5, 2023. During this call he will provide a strategic update, including the company's plans to advance APX3330 into registrational trials in diabetic retinopathy in 2024.

OIS XIII Presentation Details:
Session:	Spotlight on Oral Therapies for Retina
Date:	Saturday, December 2, 2023
Time:	2:50 to 3:50pm PT
Location:	Omni Hotel, San Diego

The presentation will be followed by a panel discussion.

Investor Conference Call and Webcast Details
Date:	Tuesday, December 5, 2023
Time:	10:00am ET
Dial-in information:	1-877-407-4018 (US); 1-201-689-8471 (International); Call me
Passcode:	13742669
Webcast link

Participants can use Guest dial-in numbers above and be answered by an operator OR click the Call me link for instant telephone access to the event. Call me link will be made active 15 minutes prior to scheduled start time.

About Ocuphire Pharma

Ocuphire Pharma, Inc. is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders.

Ocuphire’s lead retinal product candidate, APX3330, is a first-in-class small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref-1 is a regulator of the transcription factors HIF-1a and NF-kB. Inhibiting REF-1 reduces levels of vascular endothelial growth factor (“VEGF”) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. Through inhibition of Ref-1, APX3330 normalizes the levels of VEGF to physiologic levels, unlike biologics that deplete VEGF below the levels required for normal function. APX3330 is an oral tablet to be administered twice per day for the treatment of diabetic retinopathy (“DR”). A Phase 2 study in subjects with DR and an End-of-Phase 2 meeting have recently been completed, and a Special Protocol Assessment is planned to be submitted with the U.S. Food and Drug Administration (FDA).